文献速递主动脉疾病

B型主动脉夹层开放、腔内与药物治疗的比较

Comparison of type B dissection by open, endovascular, and medical treatments.
PubMed 文献 · J Vasc Surg · 2019-06-05

基于美国全国住院患者样本库2005至2012年数据,纳入54971例B型主动脉夹层患者,采用三分类倾向评分1:1:1匹配后比较开放手术、TEVAR与最佳药物治疗。TEVAR并发症更少、住院更短、费用更低。

要点

  • TEVAR死亡率低于开放手术(OR 0.60)和药物治疗(OR 0.62)。
  • 开放手术与最佳药物治疗死亡率无显著差异(OR 0.97)。
  • TEVAR并发症更少、住院更短、医疗费用更低。

核心结论

  • TEVAR在死亡率、并发症和费用方面优于开放手术或最佳药物治疗B型主动脉夹层。

研究设计与样本

  • 回顾性队列研究,使用美国全国住院患者样本库(含4378家医院)2005至2012年数据。
  • 纳入成人原发或继发B型主动脉夹层患者,排除主动脉瘤或接受心脏停搏液、瓣膜修复或心脏血管手术者。
  • 共纳入54971例患者,采用多分类逻辑回归构建三分类倾向评分,进行1:1:1匹配。

主要发现

  • TEVAR死亡率显著低于开放手术(OR 0.60;95%CI 0.46-0.79)。
  • TEVAR死亡率显著低于最佳药物治疗(OR 0.62;95%CI 0.47-0.83)。
  • 开放手术与最佳药物治疗死亡率相似(OR 0.97;95%CI 0.74-1.27)。
  • TEVAR相比开放手术并发症率更低、住院时间更短、医疗费用更低。

临床怎么用

  • 对于B型主动脉夹层患者,TEVAR可作为优于开放手术和单纯药物治疗的选择。
  • TEVAR在死亡率、并发症和费用方面均具优势,支持其临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to address the shortcomings of previous clinical trials that were inadequate to prove the superiority of thoracic endovascular aortic repair (TEVAR) in managing type B aortic dissection (TBAD) over open surgery (OS) or best medical treatment (BMT). The comparative effectiveness of these three treatments was analyzed using data of the National Inpatient Sample, a large U.S. database including patients from 4378 hospitals. METHODS: Adult patients diagnosed with a primary or secondary TBAD in the years 2005 to 2012 were included for analysis. Patients who had aortic aneurysm or received cardioplegia, valve repair, or operations on vessels of the heart were excluded. A three-category propensity score was created by using a multinomial logistic regression model, a three-way matching algorithm for 1:1:1 matching was applied, and a parallel outcome comparison between the three matched treatment groups was performed. RESULTS: Of a total of 54,971 patients included in the study, we matched 17,211 into three equal-size treatment groups (OS, 5755; TEVAR, 5695; BMT, 5761). No significant difference in the 22 baseline covariates was found in the matched cohort. We found TEVAR to have a much lower mortality rate than OS (odds ratio [OR], 0.60; 95% confidence interval [CI], 0.46-0.79) or BMT (OR, 0.62; 95% CI, 0.47-0.83). Mortality rates between OS and BMT were similar (OR, 0.97; 95% CI, 0.74-1.27). We also found TEVAR to have a lower complication rate, shorter hospitalization, and lower medical cost compared with OS. CONCLUSIONS: TEVAR is superior to BMT or OS for treatment of TBAD in terms of mortality, complications, and cost.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hsieh RW, Hsu TC, Lee M, et al. Comparison of type B dissection by open, endovascular, and medical treatments. J Vasc Surg. 2019. PMID: 31176640. doi:10.1016/j.jvs.2019.02.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。